Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A cohort study evaluating risk of hypertension in patients treated with mirabegron compared with tolterodine

Trial Profile

A cohort study evaluating risk of hypertension in patients treated with mirabegron compared with tolterodine

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Mirabegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Sep 2018 New trial record
    • 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top